The Joint Corp. Reports Fourth Quarter and Full Year 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- S&P 500, Dow set to open lower as Gulf tensions send oil to over six-week high
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Citi initiates UiPath coverage with Buy rating and $23 target
- Trump says Canada's Bombardier must build jets in US or lose market access
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- European shares subdued as surging crude sharpens focus on ECB rate path
- S&P 500, Dow set to open lower as Gulf tensions send oil to over six-week high
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
The Joint Corp (JYNT) PT Raised to $15 at DA Davidson Following 4Q
March 8, 2019 8:52 AM ESTDA Davidson analyst Michael Kawamoto raised the price target on The Joint Corp (NASDAQ: JYNT) to $15.00 (from $10.00) while maintaining a Buy rating following the company's 4Q. JYNT reported 4Q18 revenue, EBITDA, and EPS of $9.1M, $1.5M, and $0.06, compared to consensus of $8.6M, $1.2M, and $0.03.... More
The Joint Corp. (JYNT) Tops Q4 EPS by 3c, Revenues Beat; Offers FY19 Outlook
March 7, 2019 4:31 PM ESTThe Joint Corp. (NASDAQ: JYNT) reported Q4 EPS of $0.06, $0.03 better than the analyst estimate of $0.03. Revenue for the quarter came in at $9.1 million versus the consensus estimate of $8.6 million.
Building upon the foundation we laid out over the past two years, we will continue to accelerate franchise sales, further leverage our regional developer (RD) strategy, and step up the expansion of our corporate clinic portfolio... More
